through a tough time that might impact their academic budgets. Thermo Fisher remains cautious since growth could further moderate if the economic scenario worsens. The Zacks Consensus Estimate for 2024 earnings per share (EPS) has moved to $21.65 from $21.64 in the past 30 days. Some better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS) , Medpace (MEDP) and ResMed (RMD) . Medpace, also sporting a Zacks Rank #1 at present, has an estimated 2024 earnings growth rate of 27.1% compared ...

narvikk Introduction On April 24, I wrote an article covering Alexandria Real Estate Equities (ARE), a REIT that owns healthcare real estate, including laboratories. This REIT is on my radar as a fantastic way to benefit from innovation in healthcare without having to figure out which biotech company will reveal a groundbreaking drug next. [...] the company has provided the facilities that allowed for groundbreaking research, as the company noted that roughly half of all FDA-approved therapies over the past ...

VANCOUVER, BC, May 23, 2024 /PRNewswire/ - Trilogy Metals Inc. (TSX: TMO) (NYSE American: TMQ) ("Trilogy Metals" or the "Company") is pleased to announce the detailed voting results on the items of business considered at its Annual Meeting of Shareholders ("Meeting") held in Vancouver on Wednesday, May 22, 2024. All proposals were approved and the nominees listed in the management proxy circular for the meeting were all elected as directors. A total of 98,964,326 or 61.79% of the Company's issued and outsta ...

Thermo Fisher Scientific (TMO) recently introduced the Applied Biosystems Axiom BloodGenomiX Array and Software, a first-of-its-kind solution for more precise blood genotyping in clinical research. The new array detects most extended and rare blood groups, tissue (HLA) and platelet (HPA) types in a single, highthroughput assay, supporting future advancements in donor blood matching for extended phenotypes. The latest development is expected to enhance the company's Life Sciences Solutions segment, which off ...

Thermo Fisher Scientific Inc. (NYSE:TMO) Bank of America Securities 2024 Health Care Conference Call May 14, 2024 11:00 AM ET Company Participants Marc Casper - Chairman, President & Chief Executive Officer Conference Call Participants Mike Ryskin - Bank of America Mike Ryskin Thanks everyone for joining us. For those of you who don't know me, my name is Mike Ryskin on BofA life science tools and diagnostics team. And I'm thrilled to kick off the Bank of America Las Vegas Healthcare Conference. Joining us f ...

Thermo Fisher Scientific Inc. (NYSE:TMO) Bank of America Securities 2024 Health Care Conference Call May 14, 2024 11:00 AM ET Company Participants Marc Casper - Chairman, President & Chief Executive Officer Conference Call Participants Mike Ryskin - Bank of America Mike Ryskin Thanks everyone for joining us. For those of you who don't know me, my name is Mike Ryskin on BofA life science tools and diagnostics team. And I'm thrilled to kick off the Bank of America Las Vegas Healthcare Conference. Joining us f ...

Have you evaluated the performance of Thermo Fisher Scientific's (TMO) international operations during the quarter that concluded in March 2024? Considering the extensive worldwide presence of this maker of scientific instrument and laboratory supplies, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is ...

Thermo Fisher Scientific Inc.'s (TMO) first-quarter 2024 adjusted earnings per share (EPS) of $5.11 topped the Zacks Consensus Estimate by 8.7%. The figure also rose 1.6% year over year.The adjusted number excludes certain non-recurring expenses, including asset amortization costs and certain restructuring costs.GAAP EPS was $3.46, up 4.2% on a year-over-year basis.Revenues in DetailRevenues in the quarter totaled $10.35 billion, down 3.4% year over year. The top line surpassed the Zacks Consensus Estimate ...

Turning to our Specialty Diagnostics. In Q1, reported revenue and organic revenue were flat versus the prior year quarter. In Q1, we continued to see strong underlying growth in the core, led by our transplant diagnostics and immunodiagnostics businesses as well as in our healthcare market channel. Q1 adjusted operating income for Specialty Diagnostics increased 5% and adjusted operating margin was 26.5%, which is 120 basis points higher than Q1 2023. During the quarter, we delivered favorable business mix ...

For the quarter ended March 2024, Thermo Fisher Scientific (TMO) reported revenue of $10.35 billion, down 3.4% over the same period last year. EPS came in at $5.11, compared to $5.03 in the year-ago quarter.The reported revenue represents a surprise of +2.02% over the Zacks Consensus Estimate of $10.14 billion. With the consensus EPS estimate being $4.70, the EPS surprise was +8.72%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to d ...